Investment & M&A transaction comps
Clinical Skincare Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged clinical skincare. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 10
- With value data
- 8
- With revenue multiples
- 8
- Transaction years
- 2017–2026
Sortable transaction comps
Clinical Skincare transaction table
Rows with reported value
8 / 10
Acquisition EV, USD
USD 5.2B
Investment EV, USD
-
Median EV / revenue
4.8x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
10 shown of 10 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| YNS Cosmeceuticals Control | 2026-07-02 | Trilogy Laboratories | Undisclosed Undisclosed | Undisclosed | - | - | - | Confirmed 1 source | ||
| RoC Skincare Control | 2024-01-23 | Bridgepoint | EUR 462M Enterprise Value | 511 | 3.3x | 20.0x | - | Estimated 1 source | ||
| 2023-12-22 | Shiseido Company, Limited | EUR 409M Enterprise Value | 448 | 4.8x | - | New York, United States | Confirmed 1 source | |||
| Skinbetter Science Control | 2022-09-23 | L’Oréal | USD 858M Enterprise Value | 858 | 8.2x | - | United States | Confirmed 1 source | ||
| E45 Control | 2021-12-01 | Karo Healthcare | GBP 200M Enterprise Value | 267 | 4.7x | - | - | Confirmed 1 source | ||
| ALASTIN Skincare Control | 2021-11-29 | Galderma | Undisclosed Undisclosed | Undisclosed | - | 8.6x | United States | Estimated 1 source | ||
| Obagi Control | 2021-11-15 | Waldencast | EUR 756M Enterprise Value | 865 | 4.5x | 17.2x | - | Confirmed 1 source | ||
| PCA Skin and EltaMD Control | 2017-12-18 | Colgate-Palmolive | USD 730M Enterprise Value | 730 | 7.3x | - | - | Estimated 1 source | ||
| Obagi Medical Products Business Control | 2017-07-01 | Haitong International Zhonghua Finance Acquisition Fund I, L.P. | USD 190M Enterprise Value | 190 | 2.2x | 6.3x | - | Confirmed 1 source | ||
| CeraVe, AcneFree, Ambi Control | 2017-01-10 | L'Oréal | USD 1.3B Enterprise Value | 1,300 | 7.7x | - | - | Confirmed 1 source |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.